≥99% HPLCPre-filled pen

Tesamorelin

Name: Tesamorelin
Brand: Dripfy
Availability: InStock

What it is?

Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue studied for stimulating the body’s own GH production through receptor-specific activation in the pituitary. It is frequently positioned in research protocols focused on visceral adiposity, metabolic regulation, and lean-mass preservation. Tesamorelin is approved (as Egrifta) in the US and Canada solely for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; it is not authorised by the MHRA or EMA, and other uses are off-label.

Dripfy Advantage

Receptor engagement: Binds to GHRH receptors in the pituitary to stimulate endogenous GH release.
Physiological GH stimulation: Promotes GH production via the native hypothalamic–pituitary axis, supporting a more physiological endocrine activation approach.
Visceral adipose signalling: Often studied for effects on visceral fat–related endpoints, while maintaining attention to lean-tissue preservation markers.
Metabolic pathway influence: Associated with improvements in lipid markers (e.g. triglycerides) and body-composition regulation pathways; glucose regulation requires monitoring, as glucose intolerance can occur.
Protocol suitability: Commonly used where the goal is GH-axis support without exogenous GH administration, allowing clearer protocol control.

Clinical Applications & Therapeutic Potential

GHRH–GH axis activation: Enhanced endogenous GH signalling via receptor-mediated stimulation, supporting endocrine adaptation studies.
Visceral adiposity endpoints: Reductions in visceral fat–related markers with concurrent preservation of lean-mass endpoints.
Metabolic profile modulation: Improved metabolic marker patterns (e.g. triglyceride and cholesterol-ratio endpoints; glycaemic markers require monitoring) observed in structured protocols.
Body composition optimisation: Favourable recomposition dynamics with improved fat-to-lean ratio markers over time (context-dependent).

Composition & Formulation

Peptide content: 5 mg Tesamorelin acetate
Vehicle: Proprietary pH-balanced buffer solution
Delivery system: Pre-filled, multi-dose, closed-system pen
Total volume: 3 mL
Purity: ≥99% by HPLC/MS

€413

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Tesamorelin

Growth hormone–releasing hormone (GHRH) analogue · Pre-filled pen

B· Moderate evidence

Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors and stimulates the body's own GH secretion through the natural hypothalamic–pituitary axis. It is best known for, and approved only for, reducing excess visceral adipose tissue in a specific HIV-associated condition (approved by the US FDA and Health Canada; it is not authorised by the MHRA or EMA), with related improvements in lipid markers while glucose regulation requires monitoring. Its use for general lean-mass support or anti-ageing is off-label and not established by outcome trials.

Studied use areas

Research into stimulation of the endogenous GH axis
Visceral-adiposity and body-composition research
Lean-tissue-preservation research
Glucose–lipid metabolic-marker research

Safety & status

Educational information only — not medical advice; use requires physician supervision
Prescription-only medicine approved (US FDA, Health Canada) only for a specific HIV-related indication; not authorised by the MHRA or EMA, and other uses are off-label
Can affect glucose regulation and fluid balance and is not suitable in certain conditions, so clinical screening is essential
Prohibited in competitive sport: listed under WADA Prohibited List class S2 (peptide hormones, growth factors, related substances and mimetics — GHRH analogues, where tesamorelin is named)
Suitability, indication and monitoring are determined by the treating physician

⚕ Clinical note: This card is educational and is not medical advice, a protocol or a promise of results. Tesamorelin is a prescription-only medicine; any use must be individualised and supervised by a qualified physician.

Evidence: Grade B — approved (US FDA, Health Canada) for excess abdominal fat in HIV-associated lipodystrophy, supported by randomised trials; not authorised by the MHRA/EMA, and lean-mass / GH-axis uses are off-label · References: Falutz et al., New England Journal of Medicine 2007; Falutz et al., Journal of Clinical Endocrinology & Metabolism 2010; FDA prescribing information (EGRIFTA SV / EGRIFTA WR); Health Canada product monograph (EGRIFTA); EMA: withdrawal of the Egrifta marketing-authorisation application (2012)